drugset
drugset / Trial / NCT03814317

Inhaled Treprostinil in Sarcoidosis Patients With Pulmonary Hypertension

NCT03814317 ↗

Phase 2 Completed 5 enrolled University of Florida United Therapeutics · collab
NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of inhaled treprostinil in subjects with sarcoidosis-associated interstitial lung disease and pulmonary hypertension.

Timeline

Start
2020-01-30
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Treprostinil Other / unclassified 72 ug Inhaled

Indications

interstitial lung disease pulmonary hypertension sarcoidosis